The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Open accessAbstract
SUMMARY When type III interferon (IFN-λ; also known as interleukin-28 (IL-28) and IL-29) was discovered in 2003, its antiviral function was expected to be analogous to the type I IFNs (IFN-α and IFN-β), via the induction of IFN-stimulated genes (ISGs). While IFN-λ stimulates expression of antiviral ISGs preferentially in cells of epithelial origin, recent studies have defined additional antiviral mechanisms in other cell types and tissues. Models of viral infection using mice lacking IFN-λ signaling and single nucleotide polymorphism (SNP) associations with human disease have expanded our understanding of the contribution of IFN-λ to the antiviral response at anatomic barriers and the immune response beyond these barriers. In this review, we highlight recent insights into the functions of IFN-λ, including its ability to restrict virus spread into the brain and to clear chronic viral infections in the gastrointestinal tract. We also discuss how IFN-λ modulates innate and adaptive immunity, autoimmunity, and tumor progression and its possible therapeutic applications in human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O’hUigin, C., Kidd, J., Kidd, K., Khakoo, S. I., Alexander, G., et al. (2009) · Nature · doi:10.1038/nature08463 · Cited by 2,150
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., Abbas, A. R., Modrusan, Z., Ghilardi, N., de Sauvage, F. J., et al. (2008) · Nature Medicine · doi:10.1038/nm1720 · Cited by 1,921
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,826
IL-28, IL-29 and their class II cytokine receptor IL-28R
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003) · Nature Immunology · doi:10.1038/ni873 · Cited by 1,570
IL-22 Increases the Innate Immunity of Tissues
Wolk, K., Kunz, S., Witte, E., Friedrich, M., Asadullah, K., & Sabat, R. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.007 · Cited by 1,359
Cited by
Toll-like Receptors and the Control of Immunity
Fitzgerald, K. A., & Kagan, J. C. (2020) · Cell · doi:10.1016/j.cell.2020.02.041 · Cited by 2,168
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Self-citationThe continued threat of emerging flaviviruses
Pierson, T. C., & Diamond, M. S. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0714-0 · Cited by 1,098
Self-citationThe Role of Zinc in Antiviral Immunity
Read, S. A., Obeid, S., Ahlenstiel, C., & Ahlenstiel, G. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz013 · Cited by 749
Bayer, A., Lennemann, N. J., Ouyang, Y., Bramley, J. C., Morosky, S., Marques, E. T. D. A., Cherry, S., Sadovsky, Y., & Coyne, C. B. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.03.008 · Cited by 546
Galani, I. E., Triantafyllia, V., Eleminiadou, E.-E., Koltsida, O., Stavropoulos, A., Manioudaki, M., Thanos, D., Doyle, S. E., Kotenko, S. V., Thanopoulou, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.025 · Cited by 477
Negishi, H., Taniguchi, T., & Yanai, H. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028423 · Cited by 445
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Papp, K., Gordon, K., Thaçi, D., Morita, A., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., & Banerjee, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806382 · Cited by 420
Type III interferons disrupt the lung epithelial barrier upon viral recognition
Broggi, A., Ghosh, S., Sposito, B., Spreafico, R., Balzarini, F., Lo Cascio, A., Clementi, N., De Santis, M., Mancini, N., Granucci, F., et al. (2020) · Science · doi:10.1126/science.abc3545 · Cited by 402
New fronts emerge in the influenza cytokine storm
Guo, X.-Z. J., & Thomas, P. G. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0636-y · Cited by 297
Macri, C., Pang, E. S., Patton, T., & O’Keeffe, M. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.12.009 · Cited by 275
Direct Antiviral Mechanisms of Interferon-Gamma
Kang, S., Brown, H. M., & Hwang, S. (2018) · Immune Network · doi:10.4110/in.2018.18.e33 · Cited by 272
Interferon-λ orchestrates innate and adaptive mucosal immune responses
Ye, L., Schnepf, D., & Staeheli, P. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0182-z · Cited by 266
Klinkhammer, J., Schnepf, D., Ye, L., Schwaderlapp, M., Gad, H. H., Hartmann, R., Garcin, D., Mahlakõiv, T., & Staeheli, P. (2018) · eLife · doi:10.7554/elife.33354 · Cited by 264
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Duque-Correa, M. A., Karp, N. A., McCarthy, C., Forman, S., Goulding, D., Sankaranarayanan, G., Jenkins, T. P., Reid, A. J., Cambridge, E. L., Ballesteros Reviriego, C., et al. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007265 · Cited by 35
Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits
Shi, C., Ray-Jones, H., Ding, J., Duffus, K., Fu, Y., Gaddi, V. P., Gough, O., Hankinson, J., Martin, P., McGovern, A., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.01.015 · Cited by 32
Metadata
- Authors
- Lazear, H. M., Nice, T. J., & Diamond, M. S.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 43
- Issue
- 1
- Pages
- 15-28
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W1841904820
- Cited by
- 480
- References
- 150
- FWCI
- 18.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.